Modern aspects of the microbial landscape of the vagina and humoral immune response in women with chlamydia-viral cervicovaginitis. Correction of violations

Бу Вейвей, В. О. Бенюк, В. Л. Дронова, О. А. Щерба, Т. В. Ковалюк


Despite significant advances in gynecology, the frequency of sexually transmitted diseases continues to grow, accounting for 50–80% of the total number of gynecological diseases. The normal microflora of the genital tract, under certain conditions acquires pathogenic properties. Chlamydia and herpes are among the most common human infections.

The article deals with modern aspects of vaginal microbiocenosis and its correction in patients with chlamydial-viral infection of the lower genital tract. The purpose of the study was to assess the state of vaginal microbiocenosis in women with chlamydia-viral cervicovaginitis, and reduce the frequency of relapses through the use of combination therapy.

Authors of study examined 67 women with recurrent chlamydia-herpes cervicovaginitis, which were divided into 2 groups: I – 35 patients receiving the proposed treatment; II (comparison group) and 32 patients receiving traditional therapy. Therapy efficacy was evaluated during treatment and 1, 3, 6 months after. The examination included anamnestic, clinical, laboratory, bacteriological, bacteriological, immunological studies, ELISA and PCR.

In the results of clinical trials was proven clinical effectiveness of a comprehensive anti-inflammatory treatment of patients with recurrent cervicovaginitis. It is established that complex treatment with valacyclovir, azithromycin and tiloron and local solution of benzydamine for douching reduces treatment time and reduces the number of relapses. In particular, from women in group I who received the combined therapy, the complaints disappeared through 2–3 days, whereas in group II decrease itching and discomfort was noted only through 5–6 days. In addition, 88.6% of patients in group I noted the absence of side effects and bacterial eradication at the follow-up surveys.

As study authors conclude, patients with chlamydia-herpeticum cervicovaginitis have a violation of the vaginal biocenosis. Conducted comprehensive therapy is effective, leads to increase of parameters of nonspecific resistance of the organism, which contributes to the normalization of vaginal microbiocenosis.


microbiocenosis of the vagina; chlamydia; genital herpes; treatment


Beniuk, V.A. “Experience using of Valtrovir drug in patients with recurrent genital herpes.” Women Health 1 (2009): 193–5.

Beniuk, V.O., Shcherba, O.A., Lastovetska, L.D. “Etiopathogenetical approaches to diagnosis and treatment of vulvovaginal candidiasis herpes.” Women Health 9.64 (2011): 158–60.

Radzinskyi, V.E., et al. “Correction of vaginal biocoenosis disorders: march at the place or motion forward?” Reproductive Endocrinology 4.18 (2014): 92–100.

Vdovichenko, Y.P., Baskakov, P.N., Maslennikov, K.N. “Modern aspects of prevention and treatment of vulvovaginal mixed origin.” Women’s Health 6 (2009): 57–8.

Avkobyan, V.A. “Urogenital chlamydial infection: 25 Years Later.” Reproductive health of women 4.33 (2007): 188–92.

Panchenko, L.A. Herpes. Role in human pathology. Antivirals. Kharkiv. “Planeta-Print” (2014): 204 p.

Osipova, L.S., Kononenko, I.Y., Solskyi, S.Y., et al. “Genital herpes. The features of the disease and treatment in modern conditions.” The Ukrainian Journal of dermatology, venereology, cosmetology 3.46 (2012): 5–10.

Bren, L. “Genital herpes: a hidden epidemic.” FDA Consum 36.2 (2002): 10–16.

Stary, A. “European guidelines for management of Chlamydial infection.” Int J of STD and AIDS 12.3 (2001): 30–4.

GOST Style Citations

1. Бенюк, В.А. Опыт применения препарата Вальтровир у пациенток с рецидивирующим генитальным герпесом / В.А. Бенюк // Здоровье женщины. – 2009. – № 1. – С. 193–195.

2. Бенюк, В.О. Етіопатогенетичні підходи до діагностики та лікування кандидозно-герпетичного вульвовагініту / В.О. Бенюк, О.А. Щерба, Л.Д. Ластовецька // Здоровье женщины. – 2011. – № 9 (64). – С. 158–160.

3. Радзинский, В.Е. Коррекция нарушений биоценоза влагалища: марш на месте или движение вперед? / В.Е. Радзинский и соавт. / Репродуктивная эндокринология. – 2014. – № 4 (18). – С. 92–100.

4. Вдовиченко, Ю.П. Современные аспекты профилактики и лечения вульвовагинита смешанного генеза / Ю.П. Вдовиченко, П.Н. Баскаков, К.Н. Масленников // Здоровье женщины. – 2009. – № 6. – С. 57–58.

5. Авкобян, В.А. Урогенитальная хламидийная инфекция: 25 лет спустя / В.А. Авкобян // Репродуктивное здоровье женщины. – 2007. – № 4 (33). – С. 188–192.

6. Панченко, Л.А. Герпес. Роль в патологии человека. Противовирусные препараты // Харьков: «Планета-Принт». – 2014. – 204 с.

7. Осипова, Л.С. Генитальный герпес. Особенности течения и лечения в современных условиях / Л.С. Осипова, И.Я. Кононенко, С.Я. Сольский и др. // Украïнський журнал дерматологiï, венерологiï, косметологiï. – 2012. – № 3 (46). – С. 5–10.

8. Bren, L. “Genital herpes: a hidden epidemic.” FDA Consum 36.2 (2002): 10–16.

9. Stary, A. “European guidelines for management of Chlamydial infection.” Int J of STD and AIDS 12.3 (2001): 30–4.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)